⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 13, 2024The Journal of Infectious DiseasesOpen Access

Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines

Spyros Chalkias Nichole McGhee Jordan L. Whatley Brandon Essink Adam Brosz Joanne E. Tomassini Bethany Girard Darin K. Edwards Kaichun Wu Arshan Nasir Diana Lee Laura E. Avena Jing Feng Weiping Deng David C. Montefiori Lindsey R. Baden Jacqueline M. Miller Rituparna Das

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Monovalent Omicron XBB.1.5-containing vaccines were approved for coronavirus disease 2019 (COVID-19) 2023-2024 immunizations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chalkias et al. (2024) studied this question.

synapsesocial.com/papers/68e7941db6db6435877059bd https://doi.org/10.1093/infdis/jiae067

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialHuman Clinical Trial · 2024 · 40 citations
2Analysis of B‐cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines2024 · 3 citations
3Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine2024 · 1 citations
4Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results2024 · 4 citations
5Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial2024 · 1 citations

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial2024
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine Against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial <strong> </strong>2024
Effectiveness of XBB.1.5 Vaccines Against Omicron Subvariants2024
Circulating Zika and dengue IgA-NS1 marks early postnatal exposure without significant association with congenital Zika syndrome-related microcephalyThe Journal of Infectious Diseases · 2026
Influenza B Circulation and Vaccine Effectiveness Against Medically Attended Outpatient Influenza B Illness, United States, 2016–17 Through 2024–25The Journal of Infectious Diseases · 2026

More from The Journal of Infectious Diseases

More from Brigham and Women's Hospital

More from Duke Medical Center

More from Moderna Therapeutics (United States)

More from Meridian Clinical Research